Areva Pharmaceuticals Launches Temozolomide
Areva Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Temozolomide,USP5mg, 20mg 100mg, 140mg, 180mg, 250mg, It is an AB-rated product to Temodar®
“Areva Pharmaceuticals is very pleased to announce the approval of Temozolomide. This approval further cements Areva’s commitment to bringing it first oral brain cancer products to produced exclusively for US and European markets,” says Irene Swaminathan, President & Chairwomen of Areva Pharmaceuticals.
Temozolomide is an alkylating agent indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme (GBM), a type of primary brain cancer, for which it is given concomitantly with radiotherapy and then as maintenance treatment. Temozolomide is also indicated for the treatment of refractory anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine; anaplastic astrocytoma is a type of cancer that can occur within the brain and spinal cord
About Areva Pharmaceutical
Areva Pharmaceuticals Inc., a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, and more streamlined in practice for US Healthcare providers. Areva ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most. Our mission is to to work with our healthcare partners to bring innovative treatment solutions.